- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 47
- States / cities
- Daphne, Alabama • Anaheim, California • Clovis, California + 44 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 4,513
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Interventions
- Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Other · Procedure · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 624
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more
- Conditions
- Acute Kidney Injury
- Interventions
- Suramin, Placebo
- Drug
- Lead sponsor
- Rediscovery Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • La Mesa, California • Los Angeles, California + 9 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 271
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
- Conditions
- Obesity
- Interventions
- Nutrisystem
- Behavioral
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Arthroplasty, Replacement, Knee
- Interventions
- Triathlon Tritanium Cone Augments
- Device
- Lead sponsor
- Stryker Orthopaedics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 9
- States / cities
- Zephyrhills, Florida • Chicago, Illinois • Lexington, Kentucky + 6 more
- Conditions
- Chronic Graft-Versus-Host Disease (cGVHD)
- Interventions
- Vimseltinib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 26
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 22 more
- Conditions
- Right Ventricular Failure
- Interventions
- CentriMag RVAS placement
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Lexington, Kentucky • Minneapolis, Minnesota + 7 more
- Conditions
- Atopic Dermatitis
- Interventions
- tapinarof cream, 1%, vehicle cream
- Drug
- Lead sponsor
- Organon and Co
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more
- Conditions
- Phenylketonuria
- Interventions
- BMN 165
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 31
- States / cities
- La Jolla, California • Oakland, California • Aurora, Colorado + 28 more
- Conditions
- Geographic Atrophy
- Interventions
- ANX007, Sham comparator
- Drug · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 39 more
- Conditions
- Infections, Meningococcal
- Interventions
- GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
- Conditions
- Allergic Rhinitis Due to Grass Pollens
- Interventions
- 300 IR, Placebo
- Drug
- Lead sponsor
- Stallergenes Greer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more
- Conditions
- Ovarian Cancer
- Interventions
- Lapatinib and Paclitaxel
- Drug
- Lead sponsor
- Frederick R. Ueland, M.D.
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Fibromyalgia
- Interventions
- pramipexole ER, placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
- Conditions
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Interventions
- Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more
- Conditions
- Osteoporosis, Prostate Cancer
- Interventions
- Calcium, Zoledronic acid, radiation therapy, LHRH, Vitamin D
- Dietary Supplement · Radiation · Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 80
- States / cities
- Chico, California • Los Angeles, California • Pomona, California + 66 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 30
- States / cities
- Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Discussion, Medical Chart Review, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 15 Years to 39 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 480
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 302 more
- Conditions
- Obesity
- Interventions
- survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Spring Valley, California • Walnut Creek, California + 29 more
- Conditions
- Kidney Transplantation, Chronic Kidney Failure
- Interventions
- Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 29 more
- Conditions
- Anxiety Disorders
- Interventions
- tDCS
- Device
- Lead sponsor
- Thomas Adams
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Lexington, Kentucky
- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Azacitidine, Entinostat, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Lexington, Kentucky • Albuquerque, New Mexico • Dallas, Texas
- Conditions
- Adverse Events
- Interventions
- Irrisept, Standard of Care
- Device
- Lead sponsor
- Irrimax Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more